Skip to main content Accessibility help
×
×
Home

Association of high-sensitivity C-reactive protein with de novo major depression

  • Julie A. Pasco (a1), Geoffrey C. Nicholson (a1), Lana J. Williams (a1), Felice N. Jacka (a1), Margaret J. Henry (a1), Mark A. Kotowicz (a1), Hans G. Schneider (a2), Brian E. Leonard (a3) and Michael Berk (a4)...

Abstract

Background

Although there is cross-sectional evidence that changes in the immune system contribute to the pathophysiology of depression, longitudinal data capable of elucidating cause and effect relationships are lacking.

Aims

We aimed to determine whether subclinical systemic inflammation, as measured by serum high-sensitivity C-reactive protein (hsCRP) concentration, is associated with an increased risk of de novo major depressive disorder.

Method

Major depressive disorder was diagnosed using a clinical interview (SCID–I/NP). This is a retrospective cohort study; from a population-based sample of 1494 randomly selected women recruited at baseline during the period 1994–7, 822 were followed for a decade and provided measures of both exposure and outcome. Of these women, 644 (aged 20–84 years) had no prior history of depression at baseline and were eligible for analysis.

Results

During 5827 person-years of follow-up, 48 cases of de novo major depressive disorder were identified. The hazard ratio (HR) for depression increased by 44% for each standard deviation increase in log-transformed hsCRP (ln-hsCRP) (HR = 1.44, 95% CI 1.04–1.99), after adjusting for weight, smoking and use of non-steroidal anti-inflammatory drugs. Further adjustment for other lifestyle factors, medications and comorbidity failed to explain the observed increased risk for depression.

Conclusions

Serum hsCRP is an independent risk marker for de novo major depressive disorder in women. This supports an aetiological role for inflammatory activity in the pathophysiology of depression.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Association of high-sensitivity C-reactive protein with de novo major depression
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Association of high-sensitivity C-reactive protein with de novo major depression
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Association of high-sensitivity C-reactive protein with de novo major depression
      Available formats
      ×

Copyright

Corresponding author

Associate Professor Julie A. Pasco, Epidemiology and Biostatistics Unit, Department of Clinical and Biomedical Sciences, Barwon Health, The University of Melbourne, PO Box 281, Geelong 3220, Australia. Email: juliep@barwonhealth.org.au

Footnotes

Hide All

The study was funded by the Victorian Health Promotion Foundation and the National Health and Medical Research Council of Australia.

Declaration of interest

M.B. has received grant/research support from the Stanley Medical Research Foundation, MBF, National Health and Medical Research Council, Beyond Blue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier and AstraZeneca. He has been a paid consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Pfizer, and a paid speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth.

Footnotes

References

Hide All
1 Smith, RS. The macrophage theory of depression. Med Hypotheses 1991; 35: 298306.
2 Maes, M, Bosmans, E, Meltzer, HY, Scharpe, S, Suy, E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189–93.
3 Frommberger, UH, Bauer, J, Haselbauer, P, Fraulin, A, Riemann, D, Berger, M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228–33.
4 Mikova, O, Yakimova, R, Bosmans, E, Kenis, G, Maes, M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203–8.
5 Sluzewska, A, Rybakowski, J, Bosmans, E, Sobieska, M, Berghmans, R, Maes, M, et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161–7.
6 Berk, M, Wadee, AA, Kuschke, RH, O'Neill-Kerr, A. Acute phase proteins in major depression. J Psychosom Res 1997; 43: 529–34.
7 Pepys, MB, Baltz, ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141212.
8 Deodhar, SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 1989; 56: 126–30.
9 Pikhart, H, Hubacek, JA, Kubinova, R, Nicholson, A, Peasey, A, Capkova, N, et al. Depressive symptoms and levels of C-reactive protein: a population-based study. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 217–22.
10 Ford, DE, Erlinger, TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004; 164: 1010–4.
11 Panagiotakos, DB, Pitsavos, C, Chrysohoou, C, Tsetsekou, E, Papageorgiou, C, Christodoulou, G, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004; 25: 492–9.
12 Danner, M, Kasl, SV, Abramson, JL, Vaccarino, V. Association between depression and elevated C-reactive protein. Psychosom Med 2003; 65: 347–56.
13 Penninx, BW, Kritchevsky, SB, Yaffe, K, Newman, AB, Simonsick, EM, Rubin, S, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003; 54: 566–72.
14 Kop, WJ, Gottdiener, JS, Tangen, CM, Fried, LP, McBurnie, MA, Walston, J, et al. Inflammation and coagulation factors in persons 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002; 89: 419–24.
15 Bluthe, RM, Michaud, B, Poli, V, Dantzer, R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 2000; 70: 367–73.
16 Dutcher, J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 2002; 16: 410.
17 Dutcher, J. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma. Oncology (Williston Park) 2002; 16: 3.
18 Dutcher, JP, Logan, T, Gordon, M, Sosman, J, Weiss, G, Margolin, K, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6: 3442–50.
19 Dell'Osso, L, Pini, S, Maggi, L, Rucci, P, Del Debbio, A, Carlini, M, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res 2007; 62: 349–55.
20 van den Biggelaar, AH, Gussekloo, J, de Craen, AJ, Frolich, M, Stek, ML, van der Mast, RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol 2007; 42: 693701.
21 Milaneschi, Y, Corsi, AM, Penninx, BW, Bandinelli, S, Guralnik, JM, Ferrucci, L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI Study. Biol Psychiatry 2009; 65: 973–8.
22 Janssen, J, Beekman, AT, Comijs, HC, Deeg, DJ, Heeren, TJ. Late-life depression: the differences between early- and late-onset illness in a community-based sample. Int J Geriatr Psychiatry 2006; 21: 8693.
23 Henry, MJ, Pasco, JA, Nicholson, GC, Seeman, E, Kotowicz, MA. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom 2000; 3: 261–8.
24 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Research Version, Non-patient Edition (SCID–I/NP). Biometrics Research, New York State Psychiatric Institute, 2002.
25 Korn, EL, Graubard, BI, Midthune, D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997; 145: 7280.
26 Visser, M, Bouter, LM, McQuillan, GM, Wener, MH, Harris, TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131–5.
27 Hak, AE, Stehouwer, CD, Bots, ML, Polderman, KH, Schalkwijk, CG, Westendorp, IC, et al. Associations of C-reactive protein with measures of adiposity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986–91.
28 Yudkin, JS, Stehouwer, CD, Emeis, JJ, Coppack, SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–8.
29 Lemieux, I, Pascot, A, Prud'homme, D, Almeras, N, Bogaty, P, Nadeau, A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961–7.
30 Raitakari, M, Mansikkaniemi, K, Marniemi, J, Viikari, JS, Raitakari, OT. Distribution and determinants of serum high-sensitive C-reactive protein in apopulation of young adults: the Cardiovascular Risk in Young Finns Study. J Intern Med 2005; 258: 428–34.
31 Williams, LJ, Pasco, JA, Henry, MJ, Jacka, FN, Dodd, S, Nicholson, GC, et al. Lifetime psychiatric disorders and body composition: a population-based study. J Affect Disord 2009; 118: 173–9.
32 Carpenter, KM, Hasin, DS, Allison, DB, Faith, MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health 2000; 90: 251–7.
33 Kloiber, S, Ising, M, Reppermund, S, Horstmann, S, Dose, T, Majer, M, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry 2007; 62: 321–6.
34 Reichenberg, A, Yirmiya, R, Schuld, A, Kraus, T, Haack, M, Morag, A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445–52.
35 Tiemeier, H, Hofman, A, van Tuijl, HR, Kiliaan, AJ, Meijer, J, Breteler, MM. Inflammatory proteins and depression in the elderly. Epidemiology 2003; 14: 103–7.
36 Kuo, HK, Yen, CJ, Chang, CH, Kuo, CK, Chen, JH, Sorond, F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005; 4: 371–80.
37 Berk, M, Ng, F, Dean, O, Dodd, S, Bush, AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008; 29: 346–51.
38 Berk, M. Oxidative biology: new intervention opportunities in psychiatry. Acta Neuropsychiatrica 2007; 19: 259–60.
39 Galecki, P, Szemraj, J, Bienkiewicz, M, Zboralski, K, Galecka, E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277–86.
40 Wei, YC, Zhou, FL, He, DL, Bai, JR, Hui, LY, Wang, XY, et al. The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res 2009; 66: 259–66.
41 Barry, S, Clarke, G, Scully, P, Dinan, TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 2009; 23: 287–94.
42 Pasco, JA, Williams, LJ, Jacka, FN, Ng, F, Henry, MJ, Nicholson, GC, et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br J Psychiatry 2008; 193: 322–6.
43 Hamalainen, J, Kaprio, J, Isometsa, E, Heikkinen, M, Poikolainen, K, Lindeman, S, et al. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health 2001; 55: 573–6.
44 Malhi, GS, Berk, M. Does dopamine dysfunction drive depression? Acta Psychiatr Scand 2007; 115 (suppl 433): 116–24.
45 Kangavari, S, Matetzky, S, Shah, PK, Yano, J, Chyu, KY, Fishbein, MC, et al. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther 2004; 9: 291–8.
46 Blumenfeld, Z, Boulman, N, Leiba, R, Siegler, E, Shachar, S, Linn, R, et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest 2007; 67: 257–63.
47 Danese, A, Pariante, CM, Caspi, A, Taylor, A, Poulton, R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA 2007; 104: 1319–24.
48 Danese, A, Moffitt, TE, Pariante, CM, Ambler, A, Poulton, R, Caspi, A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008; 65: 409–15.
49 Yuan, G, Zhou, L, Tang, J, Yang, Y, Gu, W, Li, F, et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract 2006; 72: 244–50.
50 Danesh, J, Wheeler, JG, Hirschfield, GM, Eda, S, Eiriksdottir, G, Rumley, A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–97.
51 Pasco, JA, Kotowicz, MA, Henry, MJ, Nicholson, GC, Spilsbury, HJ, Box, JD, et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006; 296: 1353–5.
52 Nilsson, K, Gustafson, L, Hultberg, B. C-reactive protein: vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn Disord 2008; 26: 251–6.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Association of high-sensitivity C-reactive protein with de novo major depression

  • Julie A. Pasco (a1), Geoffrey C. Nicholson (a1), Lana J. Williams (a1), Felice N. Jacka (a1), Margaret J. Henry (a1), Mark A. Kotowicz (a1), Hans G. Schneider (a2), Brian E. Leonard (a3) and Michael Berk (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *